LYEL Stock Overview A clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Lyell Immunopharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Lyell Immunopharma Historical stock prices Current Share Price US$0.60 52 Week High US$3.26 52 Week Low US$0.55 Beta -0.36 1 Month Change -6.92% 3 Month Change -36.19% 1 Year Change -71.19% 3 Year Change -89.35% 5 Year Change n/a Change since IPO -96.42%
Recent News & Updates
Lyell Immunopharma Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule Jan 26
Lyell Immunopharma Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule Jan 25
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference Jan 09
Consensus revenue estimates increase by 94% Dec 24
Consensus revenue estimates fall by 17% Dec 12
Lyell Immunopharma, Inc. Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-Cell Lymphoma At the 2024 ASH Annual Meeting Dec 10 See more updates
Lyell Immunopharma Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule Jan 26
Lyell Immunopharma Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule Jan 25
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference Jan 09
Consensus revenue estimates increase by 94% Dec 24
Consensus revenue estimates fall by 17% Dec 12
Lyell Immunopharma, Inc. Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-Cell Lymphoma At the 2024 ASH Annual Meeting Dec 10
Third quarter 2024 earnings released: US$0.17 loss per share (vs US$0.20 loss in 3Q 2023) Nov 08 Lyell Immunopharma, Inc. (NasdaqGS:LYEL) completed the acquisition of ImmPACT Bio USA Inc. Nov 01
Lyell Immunopharma, Inc. (NasdaqGS:LYEL) entered into an agreement and plan of merger to acquire ImmPACT Bio USA Inc. for $87.5 million. Oct 25
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth Oct 25 Lyell Immunopharma, Inc. (NasdaqGS:LYEL) entered into an agreement and plan of merger to acquire ImmPACT Bio USA Inc. for $87.5 million. Oct 25
Consensus revenue estimates increase by 52,616% Aug 20
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.26 loss in 2Q 2023) Aug 08
Price target decreased by 44% to US$3.67 Jun 27
Consensus EPS estimates fall by 0.05% Jun 27
Lyell Immunopharma Reports Dose-Dependent Clinical Activity from Phase 1 Trial of Lyl797, A Ror1-Targeted Car-T Cell Product Candidate Enhanced with Its Proprietary Anti-Exhaustion Technology Jun 26
Consensus revenue estimates increase by 400% May 13
First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023) May 07
Insufficient new directors May 01
New minor risk - Shareholder dilution Apr 23
Lyell Immunopharma, Inc., Annual General Meeting, Jun 14, 2024 Apr 23
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts Apr 16
Full year 2023 earnings released: US$0.94 loss per share (vs US$0.74 loss in FY 2022) Feb 29
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth Feb 23 Phoenix Biotech Acquisition Corp. (NasdaqGM:PBAX) completed the acquisition of CERo Therapeutics, Inc. Feb 16
New major risk - Share price stability Nov 15
Consensus revenue estimates increase by 378% Nov 14
Price target decreased by 7.1% to US$6.50 Nov 12
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth Nov 09
Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.28 loss in 3Q 2022) Nov 09
Lyell Immunopharma, Inc. Presents New Nonclinical Data at 38th Annual Meeting of SITC on Innovations Designed to Shorten Tumor Infiltrating Lymphocyte Manufacturing, LYL119 as Well as Data on New Technologies and Design of its Two Clinical Trials in Progress Nov 01
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's Car T-Cell Therapy on Cellares' Cell Shuttle Platform Sep 12
Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher Aug 29
Consensus revenue estimates increase by 25% Aug 29
Founder & Executive Chairman recently sold US$132k worth of stock Aug 20
Founder & Executive Chairman notifies of intention to sell stock Aug 18
Consensus revenue estimates decrease by 96%, EPS upgraded Aug 15
We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth Aug 11
Second quarter 2023 earnings released: US$0.26 loss per share (vs US$0.15 loss in 2Q 2022) Aug 09
Lyell Immunopharma, Inc. Appoints Matthew Lang as Chief Business Officer Jul 06
New major risk - Share price stability Jun 18
Lyell Immunopharma, Inc. Announce Resignation of Rahsaan Thompson as the Chief Legal Officer Jun 08
Price target decreased by 23% to US$7.25 Jun 02
Consensus revenue estimates decrease by 87%, EPS upgraded May 11
First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.28 loss in 1Q 2022) May 06
Price target decreased by 7.8% to US$9.40 Mar 05
Price target decreased by 9.3% to US$9.80 Mar 02
Full year 2022 earnings released: US$0.74 loss per share (vs US$1.84 loss in FY 2021) Mar 01 Lyell Immunopharma, Inc. Appoints Lynn Seely as President
Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans Dec 15
Consensus revenue estimates increase by 18% Nov 16
High number of new directors Nov 16
Price target decreased to US$12.80 Nov 12
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 09
Lyell Immunopharma Announces Fda Clearance of Its Ind for Lyl845, A Til Product Candidate Enhanced with Its Novel Epigenetic Reprogramming Technology for Solid Tumors Oct 07
Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845 Oct 06
Founder & Executive Chairman recently sold US$71k worth of stock Sep 29
Lyell Immunopharma, Inc. Announces the Appointment of Rahsaan W. Thompson as Chief Legal Officer Sep 29
Founder & Executive Chairman notifies of intention to sell stock Sep 25
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth Sep 12
Consensus forecasts updated Aug 13
News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts Aug 08
Second quarter 2022 earnings released: US$0.15 loss per share (vs US$1.47 loss in 2Q 2021) Aug 05 Lyell Immunopharma, Inc.(NasdaqGS:LYEL) dropped from Russell 2000 Growth Index
Consensus revenue estimates increase by 28% May 17
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 11
Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting May 03
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth Apr 29
High number of new directors Apr 27
Full year 2021 earnings: EPS and revenues exceed analyst expectations Apr 01
Consensus revenue estimates increase by 37% Mar 31
Independent Director exercised options to buy US$6.9m worth of stock. Feb 26
Lyell Immunopharma Announces Executive Changes Feb 01
Lyell Immunopharma, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug for LYL132 Jan 25
High number of new directors Dec 31
We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth Dec 31
Lyell Immunopharma, Inc. Announces FDA Clearance of its IND for LYL797 Dec 18
Lyell Immunopharma, Inc. Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs Dec 16
Third quarter 2021 earnings released: US$0.20 loss per share Nov 15
Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation Sep 17
Lyell Immunopharma, Inc. has completed an IPO in the amount of $425 million. Jun 18 Shareholder Returns LYEL US Biotechs US Market 7D 5.1% 3.6% 1.8% 1Y -71.2% -3.7% 24.9%
See full shareholder returns
Return vs Industry: LYEL underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: LYEL underperformed the US Market which returned 24.9% over the past year.
Price Volatility Is LYEL's price volatile compared to industry and market? LYEL volatility LYEL Average Weekly Movement 14.4% Biotechs Industry Average Movement 11.3% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: LYEL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LYEL's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Founded Employees CEO Website 2018 224 Lynn Seely lyell.com
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications.
Show more Lyell Immunopharma, Inc. Fundamentals Summary How do Lyell Immunopharma's earnings and revenue compare to its market cap? LYEL fundamental statistics Market cap US$176.76m Earnings (TTM ) -US$203.99m Revenue (TTM ) US$63.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LYEL income statement (TTM ) Revenue US$63.00k Cost of Revenue US$0 Gross Profit US$63.00k Other Expenses US$204.05m Earnings -US$203.99m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.70 Gross Margin 100.00% Net Profit Margin -323,792.06% Debt/Equity Ratio 0%
How did LYEL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/27 04:30 End of Day Share Price 2025/01/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Lyell Immunopharma, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Geoffrey Meacham BofA Global Research Jason Zemansky BofA Global Research Salveen Richter Goldman Sachs
Show 5 more analysts 
